FA
LEGN icon

Forefront Analytics’s Legend Biotech LEGN Stock Holding History

Forefront Analytics’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Sell
10,568
-5,091
-33% -$137K 0.33% 27
2026
Q1 		$283K Buy
+15,659
New +$299K 0.26% 28
2025
Q2 		– Sell
-6,429
Closed -$219K – 50
2025
Q1 		$219K Buy
+6,429
New +$231K 0.25% 32

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Forefront Analytics's LEGN Position: Q2 2026 in Review

Forefront Analytics reduced its Legend Biotech (LEGN) stake by 33% in Q2 2026, selling an estimated $137K and leaving 10,568 shares worth $305K. The position accounts for 0.33% of the portfolio, ranked #27.

Forefront Analytics first reported a position in LEGN in Q1 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Forefront Analytics held 10,568 shares of Legend Biotech worth $305K as of Q2 2026.
  • Forefront Analytics sold 5,091 Legend Biotech shares in Q2 2026, an estimated $137K.
  • Legend Biotech made up 0.33% of Forefront Analytics's portfolio in Q2 2026, its #27 holding.
  • Forefront Analytics first reported a position in Legend Biotech in Q1 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Forefront Analytics's 13F filing for Q2 2026, filed 13 Aug 2026.